Cantor Fitzgerald initiates its rating on ImmunoGen IMGN with a Hold rating and a price target of $15.
Cantor Fitzgerald comments, "ImmunoGen is approaching commercial revenue via a partnership with Roche, and this is a solid positive for the stock. However, much of the good news is in the valuation and another catalyst is needed for greater appreciation, in our view."
IMGN closed at $15 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in